Glaukos Corporation (NYSE:GKOS) Q2 2023 Earnings Call Transcript
Operator: Welcome to Glaukos Corporation's Second Quarter 2023 Financial Results Conference Call.
Posts Tagged ‘NYSE:GKOS’
Glaukos Corporation (NYSE:GKOS) Q1 2023 Earnings Call Transcript
Operator: Welcome to Glaukos Corporation’s First Quarter 2023 Financial Results Conference Call.
Glaukos Corporation (NYSE:GKOS) Q4 2022 Earnings Call Transcript
Operator: Welcome to Glaukos Corporation's Fourth Quarter and Full Year 2022 Financial Results Conference Call.
Foreign Currency Headwinds Dragged Glaukos Corporation (GKOS) Shares in Q4
Alger Capital, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” fourth quarter 2022 investor letter.
5 Small Innovative Companies According to the Media
In this piece, we will take a look at the five small innovative companies according to the media.
15 Largest Ophthalmology Companies in the World
In this article, we will take a look at the 15 largest ophthalmology companies in the world.
Hedge Funds Are Piling Into Glaukos Corporation (GKOS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Here’s Why Artisan Partners Sold its Glaukos Corp. (GKOS) Stake
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ third quarter 2021 investor letter – a copy of which can be downloaded...
Hedge Funds Are Warming Up To Glaukos Corporation (GKOS)
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Here’s Why Artisan Partners Sold its Glaukos Corporation (GKOS) Position
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ second quarter 2021 investor letter – a copy of which can be downloaded...
Glaukos Corporation (GKOS): Are Hedge Funds Right About This Stock?
Is Glaukos Corporation (NYSE:GKOS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment...
Artisan Partners: “We Believe Glaukos Corp. (GKOS) has Significant Profit-Cycle Potential”
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded...
Is GKOS A Good Stock To Buy Now?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Glaukos Corporation (GKOS): Hedge Fund Interest Inching Up
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file ...
Here is What Hedge Funds Think About Glaukos Corporation (GKOS)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Were Hedge Funds Right About Glaukos Corporation (GKOS) ?
Coronavirus is probably the #1 concern in investors' minds right now. It should be.
Is Glaukos Corporation (GKOS) Going to Burn These Hedge Funds?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Glaukos Corporation (GKOS): Hedge Funds Aren’t Excited
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock.
This Is What Hedge Funds Think About Glaukos Corporation (GKOS)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter.
Did Hedge Funds Drop The Ball On Glaukos Corporation (GKOS)?
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock.
Hedge Funds Are Betting On Glaukos Corporation (GKOS)
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions...
Hedge Fund Ownership of Glaukos Corp (GKOS) Triples in 3 Quarters: Are You Missing Out?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset...
Cupps Capital Slashes Portfolio in Q3, But Couldn’t Stop Buying These 5 Stocks
Drew Cupps' Chicago-based asset management firm, Cupps Capital Management, has been in the news of late after it announced that its five-member investment team will be joining...
Here’s Why Eleven Bio, SouFun, Glaukos, Match Group, and Triumph Group Are Surging Today
U.S. stocks continue to tumble on Wednesday, driven by weak economic data out of the U.S, disappointing corporate financial results, and declining metal prices.
What You Need to Know About These 4 Stocks Deep in the Red Today
Volatility isn't going away on the 13th day of the year, as all three indexes are now in the red after opening up substantially higher in the morning.
Do Hedge Funds Love Glaukos Corp (GKOS)?
The worries about the economic slowdown in China and the ongoing uncertainty about the path of interest-rate increases triggered several waves of equity sell-offs during the third...
Why Are These Four Stocks Hot on The Market on Wednesday?
Four stocks jumped into the green territory by midday on November 11 on the back of an Initial Public Offering, the involvement in legal matters, as well as the disclosure of...
Samuel Isaly’s New Healthcare Positions: Community Health Systems (CYH), Glaukos Corp (GKOS), More
Samuel Isaly’s OrbiMed Advisors is a healthcare fund with $15 billion worth of assets under management.
Samuel Isaly’s OrbiMed Advisors Discloses Large Stake in Glaukos Corp (GKOS) After Its IPO
Glaukos Corp (NYSE:GKOS) is an $870 million developer of products for the treatment of glaucoma, which conducted its IPO last week with 6.90 million shares at $18.00 per unit.
